| Literature DB >> 21984396 |
Srikant Kumar Sahu1, Savitri Sharma, Sujata Das.
Abstract
AIM: This study aims to describe the clinical features and management of Nocardia scleritis.Entities:
Year: 2011 PMID: 21984396 PMCID: PMC3303001 DOI: 10.1007/s12348-011-0043-9
Source DB: PubMed Journal: J Ophthalmic Inflamm Infect ISSN: 1869-5760
Clinical summary, management, and outcome of all reported cases of isilated Nocardia scleritis
| Sl no. | Author | Eye | Age | Sex | Predisposing factor | Duration of symptoms | Presenting VA | Final VA | Treatment—medical | Treatment—surgical | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kattan [ | OD | 63 | F | Scleral buckle, cataract surgery | 2 weeks | 1/200 | NA | Topical and TMP-SMX (iv) | Eviseration | Eviseration |
| 2 | King [ | OD | 77 | M | Scleral buckle, cataract surgery | 14 weeks | 20/60 | 20/40 | Topical 10% sulphacetamide, TMP-SMX (iv) | Buckle removal | Resolved |
| 3 | Brooks [ | OS | 90 | F | Cataract surgery | 5 weeks | 20/80 | NA | Topical amikacin, topical and oral TMP-SMX | Surgical debridement, scleral patch graft | Resolved |
| 4 | Basti [ | OD | 58 | M | Injury with vegetable material, steroids | 1 month | 20/200 | 20/40 | Cefazolin (systemic and topical) | Nil | Resolved |
| 5 | Knox [ | OS | 83 | M | Explantation of exposed buckle, steroids | NA | 20/100 | 20/60 | Topical amikacin 2.5%, TMP-SMX 160/800 | Nil | Resolved |
| 6 | Choudhry [ | OS | 54 | M | Steroids | 7 Weeks | 20/30 | NA | Cefazolin (systemic and topical), TMP-SMX 160/800, 10% sulphacetamide | Surgical debridement | Worsened and lost to follow up |
| 7 | Das [ | OS | 40 | F | Mud splash, steroids | 7 weeks | 20/20 | 20/20 | Topical TMP-SMX 160/800, amikacin 2.5%, amoxycillin/clavulanate (800/125 mg) | Nil | Resolved |
| 8 | Seth [ | OD | 80 | F | Subtenon steroid | 3 months | 20/400 | CF 1 m | Topical trimetho prim/polymixin B, minocycline 100 mg/day | Scleral exploration and biopsy and bovine pericardium patch graft | Resolved |
| 9 | Jain [ | OD-2 OS-1 | 60.66 ± 7.36 | M-3 | Scleral buckle— | 1–2 months | 20/125–20/400 | 20/80–20/400 | Topical amikacin—all cases, TMP-SMX 160/800— | Debridement | Resolved—all |
| 10 | DeCroos [ | OD-8 OS-3 | 56.8 ± 13 | M-11 | Injury with organic material— | 30.4 ± 16.8 days | Mean BCVA—20/502 | Mean BCVA—20/399 | Topical amikacin/ciprofloxacin/cefazolin— | Surgical debridement— | Resolved |
| Scleral buckle— | Systemic amikacin— | ||||||||||
| PPV— | |||||||||||
| 11 | Maruo [ | OS | 78 | M | Cataract surgery | 2 months | 20/30 | 20/16 | Topical tobramycin, moxifloxacin, oral TMP-SMX | Debridement | Resolved |
OD right eye, OS left eye, NA not available, VA visual acuity, TMP-SMX trimethoprim 160–800, PPV pars plana vitrectomy
Fig. 1Patient no. 2. a Slit lamp picture showing an area of circumscribed scleral abscess. A scleral ulcer is situated inferior to the abscess. b Scleral scraping showing thin, branching, acid fast filaments (arrow) suggestive of Nocardia species (Kinyoun’s acid fast stain using 1% H2SO4, ×1,000). c Three weeks after treatment decipitating uveal show. d Healthy and vascularized graft 4 months after scleral patch graft
In vitro antibiotic susceptibility (by Kirby Bauer disk diffusion technique)
| Amikacin | Cefazolin | Chloramphenicol | Ciprofloxacin | Gatifloxacin | Ofloxacin | Vancomycin | |
|---|---|---|---|---|---|---|---|
| Case 1 | + | + | + | + | + | ND | ND |
| Case2 | + | − | − | + | + | + | − |
| Case 3 | + | − | + | − | + | − | + |
+ sensitive, − resistant, ND not done